Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Tessa Therapeutics Appoints Thomas Willemsen as President and CEO
Posted: August 22, 2022 at 2:55 am
Seasoned pharmaceutical industry executive to lead Tessa’s corporate and development strategy built around its proprietary autologous and allogeneic CAR-T platforms
See the rest here:
Tessa Therapeutics Appoints Thomas Willemsen as President and CEO
Posted in Global News Feed
Comments Off on Tessa Therapeutics Appoints Thomas Willemsen as President and CEO
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Posted: August 22, 2022 at 2:55 am
Basel, Switzerland, 22 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm CET.
See the original post:
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Posted in Global News Feed
Comments Off on Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy
Posted: August 22, 2022 at 2:55 am
Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA).
Posted in Global News Feed
Comments Off on Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Posted: August 22, 2022 at 2:55 am
Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced the signing of an agreement with YA II PN, Ltd, an exempted company incorporated in the Cayman Islands with limited liability, a company of the group of companies managed by Yorkville Advisors Global LP, its investment manager ("Yorkville"), for a financing via the issuance of convertible notes of up to CHF 20 million, to be drawn in tranches.
Continued here:
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Posted in Global News Feed
Comments Off on Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Annual Financial Report
Posted: August 22, 2022 at 2:55 am
DXS INTERNATIONAL PLC
See original here:
Annual Financial Report
Posted in Global News Feed
Comments Off on Annual Financial Report
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Posted: August 14, 2022 at 2:33 am
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.
Read this article:
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Posted in Global News Feed
Comments Off on Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Spectral Announces Second Quarter Results and Provides Corporate Update
Posted: August 14, 2022 at 2:33 am
TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Go here to read the rest:
Spectral Announces Second Quarter Results and Provides Corporate Update
Posted in Global News Feed
Comments Off on Spectral Announces Second Quarter Results and Provides Corporate Update
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Posted: August 14, 2022 at 2:33 am
—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment
Excerpt from:
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Posted in Global News Feed
Comments Off on Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever
Posted: August 14, 2022 at 2:33 am
Acquisition will create a vertically integrated Colorado cannabis company, significantly accelerating Bespoke’s growth strategy
View original post here:
Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever
Posted in Global News Feed
Comments Off on Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
Posted: August 14, 2022 at 2:33 am
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan
Go here to see the original:
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
Posted in Global News Feed
Comments Off on SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders